New drug targets Hard-to-Treat prostate cancer

NCT ID NCT03725761

Ongoing Disease control Sponsor: University of Wisconsin, Madison Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial is testing a drug called sacituzumab govitecan in 31 men with metastatic castration-resistant prostate cancer that has worsened despite hormone therapy. The drug works like a smart bomb, delivering chemotherapy directly to cancer cells. Researchers are measuring how many men have a significant drop in PSA levels and how long they live without the cancer getting worse.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Sacituzumab govitecan (a drug that targets cancer cells and delivers chemotherapy directly to them)
What this could lead to: If successful, this could provide a new treatment option for men with advanced prostate cancer that no longer responds to standard hormone therapies.
What could go wrong: This is a small, early-phase study with only 31 participants, so results may not apply to all patients. The drug can cause side effects like nausea, low blood cell counts, and diarrhea.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

Contacts and locations

Locations

Memorial Sloan-Kettering Cancer Center

New York, New York, 10065, United States
University of Wisconsin Carbone Cancer Center

Madison, Wisconsin, 53792, United States
Weill Cornell Medical College

New York, New York, 10065, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.